OG217SC (NN9924)

:Type 2 diabetes
:Phase 2

A long-acting oral GLP-1 analogue intended as once-daily tablet treatment.

Company announcements
Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes (20 Feb 2015)
Read more company announcements

Press releases
Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue (13 Jan 2010)
Read more press releases

Scientific abstracts

No scientific abstracts matching the search criteria

You can search for more clinical trials on http://clinicaltrials.gov